S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:CERC

Cerecor Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$2.09
-0.08 (-3.69%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.04
$2.15
50-Day Range
$2.06
$3.24
52-Week Range
$1.98
$4.50
Volume
233,942 shs
Average Volume
1.27 million shs
Market Capitalization
$200.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.44

Receive CERC News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerecor and its competitors with MarketBeat's FREE daily newsletter.


Cerecor logo

About Cerecor

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CERC
Fax
N/A
Employees
31
Year Founded
N/A

Sales & Book Value

Annual Sales
$6.70 million
Book Value
$0.22 per share

Profitability

Net Income
$-63.50 million
Net Margins
-1,194.82%
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$200.66 million
Optionable
Optionable

Company Calendar

Last Earnings
8/01/2021
Today
11/27/2021

MarketRank

Overall MarketRank

2.48 out of 5 stars

Medical Sector

125th out of 1,392 stocks

Pharmaceutical Preparations Industry

52nd out of 670 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Cerecor (NASDAQ:CERC) Frequently Asked Questions

Is Cerecor a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerecor in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cerecor stock.
View analyst ratings for Cerecor
or view top-rated stocks.

How were Cerecor's earnings last quarter?

Cerecor Inc. (NASDAQ:CERC) announced its quarterly earnings data on Sunday, August, 1st. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.01. The firm earned $3.36 million during the quarter. Cerecor had a negative trailing twelve-month return on equity of 261.82% and a negative net margin of 1,194.82%.
View Cerecor's earnings history
.

What price target have analysts set for CERC?

4 analysts have issued 1 year price targets for Cerecor's shares. Their forecasts range from $4.00 to $9.00. On average, they expect Cerecor's stock price to reach $6.75 in the next year. This suggests a possible upside of 223.0% from the stock's current price.
View analysts' price targets for Cerecor
or view top-rated stocks among Wall Street analysts.

Who are Cerecor's key executives?

Cerecor's management team includes the following people:
  • Michael F. Cola, Chairman & Chief Executive Officer
  • Schond L. Greenway, Chief Financial Officer & Treasurer
  • H. Jeffrey Wilkins, Chief Medical Officer
  • Garry Arthur Neil, Chief Scientific Officer (LinkedIn Profile)
  • Younok Dumortier Shin, Chief Technology Officer

What other stocks do shareholders of Cerecor own?

What is Cerecor's stock symbol?

Cerecor trades on the NASDAQ under the ticker symbol "CERC."

Who are Cerecor's major shareholders?

Cerecor's stock is owned by a number of retail and institutional investors. Top institutional investors include Citadel Advisors LLC (0.00%). Company insiders that own Cerecor stock include Armistice Capital Master Fund, Armistice Capital, Llc, Cerecor Inc, Christopher Ryan Sullivan, Garry Arthur Neil, James Archie Harrell Jr, Joseph M Miller and Michael F Cola.
View institutional ownership trends for Cerecor
.

Which major investors are selling Cerecor stock?

CERC stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC.
View insider buying and selling activity for Cerecor
or view top insider-selling stocks.

What is Cerecor's stock price today?

One share of CERC stock can currently be purchased for approximately $2.09.

How much money does Cerecor make?

Cerecor has a market capitalization of $200.66 million and generates $6.70 million in revenue each year. The company earns $-63.50 million in net income (profit) each year or ($0.57) on an earnings per share basis.

How many employees does Cerecor have?

Cerecor employs 31 workers across the globe.

What is Cerecor's official website?

The official website for Cerecor is www.cerecor.com.

Where are Cerecor's headquarters?

How can I contact Cerecor?

Cerecor's mailing address is 540 Gaither Road Suite 400, Rockville MD, 20850. The company can be reached via phone at (410) 522-8707 or via email at [email protected].


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.